admin November 16, 2017

No standard of care has been established for patients with progressive glioblastoma. Previous studies suggested that bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor, is safe and produces responses that result in a decreased use of glucocorticoids and increased…

Read More...

Leave a comment.

Your email address will not be published. Required fields are marked*

Andoird App
Loading...